Biopharma firm Suven Life Sciences on Wednesday said it has been granted two patents from Canada and one patent in China for a drug used in the treatment of neurodegenerative diseases. Neurodegenerative diseases include Alzheimer's, Schizophrenia and Parkinson's. In a BSE filing, the company said it has been granted "two product patents from Canada and one product patent from China corresponding to their New Chemical Entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases." These patents are valid through 2029 and 2030, the company added.
Suven Life Sciences CEO Venkat Jasti said, "We are very pleased by the grant of these patents to Suven for our pipeline of molecules in the central nervous system (CNS) arena that are being developed for major depressive disorders (MDD) with high unmet medical need with huge market potential globally." With this development, Suven Life Sciences' total count of patents stands at 20 from Canada and 18 from China. Shares of the company were trading at Rs 243 apiece, up 4.79 percent, on BSE in the morning trade.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
